Fosun Pharma – Another Artesunate Combination passed PQ Certification
On May 24, 2012, WHO Prequalification Program published in its website to add the Co-blister of artesunate tablet (50mg) + sulfadoxine/pyrimethamine tablet (500mg/25mg) produced by Guilin Pharmaceutical Co., Ltd. into its prequalified list. By now, Guilin Pharmaceutical has 5 antimalarial drugs added in the prequalified list of WHO Prequalification Program (namely, artesunate tablet, amodiaquine tablet, Co-blister of artesunate tablet + amodiaquine HCl tablet, artesunate powder for injection, and Co-blister of artesunate tablet and sulfadoxine/pyrimethamine tablet), and continues to be a leader in the field of antimalarial drugs in China.
As a member company of Fosun Pharma Group, Guilin Pharma not only owns a complete Artemisia industrial chain in the field of antimalarine, but also the artesunate tablet and corresponding series of products developed by it independently are first of the kind in the world, have become the top choice for the international antimalarial realm and a foreign aid drug designated by the Ministry of Commerce and the Ministry of Foreign Affairs of the People’s Republic of China. It is reported that the co-blister of artesunate tablet and sulfadoxine/pyrimethamine tablet is one of the combination solutions on the basis of artemisinin drugs (shortened as “ACT treatment”) recommended by WHO to treat falciparum malaria. At present, international organizations, including the World Health Organization (WHO), the United Nations International Children's Emergency Fund (UNICEF), Médecins Sans Frontières (MSF) and International Committee of the Red Cross (ICRC), are purchasing it to put into Sudan, Yemen, Pakistan, Afghanistan and other countries to treat local malarial patients.
PQ is an abbreviation of Pre-Qualification. WHO specifies that medicines and their manufacturers to be included in the prequalified products list of WHO should implement WHO medicine registration specifications and pass documentation review, GMP and GCP site audit in medicine quality, safety and efficacy to pass PQ certification. All pharmaceutical manufacturers wish to have their products pass PQ certification of WHO, for it will win them a pass to enter the international mainstream market of medicines. Included among the prequalified products list, the pharmaceutical manufacturers can benefit from largely improved global fame and reputation, with a premium effect far more than spread in the global market. To further carry out its strategy of global development, Guilin Pharma has been cooperating with WHO for years, making continuous innovations and improving hardware and software circumstances of product manufacturing in accordance with the international standard. During the cooperation, WHO experts and domestic experts have been frequently invited to provide guidance and training in the company. This time, the fact that the co-blister of artesunate tablet and sulfadoxine/pyrimethamine tablet passed PQ certification symbolizes that Guilin Pharmaceutical has made another milestone breakthrough in its growth way toward internationalization, and once again takes the lead in the field of antimalarial drugs in China.
As a member company of Fosun Pharma Group, Guilin Pharma not only owns a complete Artemisia industrial chain in the field of antimalarine, but also the artesunate tablet and corresponding series of products developed by it independently are first of the kind in the world, have become the top choice for the international antimalarial realm and a foreign aid drug designated by the Ministry of Commerce and the Ministry of Foreign Affairs of the People’s Republic of China. It is reported that the co-blister of artesunate tablet and sulfadoxine/pyrimethamine tablet is one of the combination solutions on the basis of artemisinin drugs (shortened as “ACT treatment”) recommended by WHO to treat falciparum malaria. At present, international organizations, including the World Health Organization (WHO), the United Nations International Children's Emergency Fund (UNICEF), Médecins Sans Frontières (MSF) and International Committee of the Red Cross (ICRC), are purchasing it to put into Sudan, Yemen, Pakistan, Afghanistan and other countries to treat local malarial patients.
PQ is an abbreviation of Pre-Qualification. WHO specifies that medicines and their manufacturers to be included in the prequalified products list of WHO should implement WHO medicine registration specifications and pass documentation review, GMP and GCP site audit in medicine quality, safety and efficacy to pass PQ certification. All pharmaceutical manufacturers wish to have their products pass PQ certification of WHO, for it will win them a pass to enter the international mainstream market of medicines. Included among the prequalified products list, the pharmaceutical manufacturers can benefit from largely improved global fame and reputation, with a premium effect far more than spread in the global market. To further carry out its strategy of global development, Guilin Pharma has been cooperating with WHO for years, making continuous innovations and improving hardware and software circumstances of product manufacturing in accordance with the international standard. During the cooperation, WHO experts and domestic experts have been frequently invited to provide guidance and training in the company. This time, the fact that the co-blister of artesunate tablet and sulfadoxine/pyrimethamine tablet passed PQ certification symbolizes that Guilin Pharmaceutical has made another milestone breakthrough in its growth way toward internationalization, and once again takes the lead in the field of antimalarial drugs in China.